USA's QMSR Shockwave: Pure Global on Surviving FDA's New Audit Game

The FDA has officially replaced the long-standing QSIT inspection model with a new approach under the Quality Management System Regulation (QMSR). This shift towards harmonization with ISO 13485 introduces a more holistic, risk-based auditing process, catching many MedTech manufacturers off guard and rendering their old preparation methods obsolete. This episode of MedTech Global Insights dives into what this change really means for your operations. We explore the critical differences between the old and new inspection techniques and the immediate impact on quality assurance teams. **Case In Point:** A manufacturer of infusion pumps, confident in their CAPA and Design Control subsystems, recently faced a QMSR audit. Instead of following the old checklist, the inspector focused entirely on the risk management files and post-market complaint data for a single product line, uncovering gaps in their risk-to-complaint process that the previous QSIT audit never would have flagged. **In This Episode, We Ask:** - Is your quality system truly integrated, or just a collection of compliant subsystems? - How does the new QMSR inspection approach change the way you should manage suppliers? - What are the key differences in documentation an investigator will now demand? - Does your current risk management process stand up to a full product lifecycle trace audit? - How can you leverage your ISO 13485 certification for the new FDA inspections? - What immediate changes should you make to your internal audit program? - Are your teams trained to speak to processes and risks, not just procedures? To ensure your quality system is ready for this new era, contact us at [email protected] or visit https://pureglobal.com/. For free AI tools and access to a comprehensive medical device database, visit https://pureglobal.ai/.